Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Top 10 Most Recent Blog Posts
Are Meme Stocks Simply Modern Pump and Dumps?
Category: Stocks Total Views: 79By : Editor Updated: 05-15-2024
Stock Market Midday Update - May 15, 2024
Category: Markets Total Views: 90By : Editor Updated: 05-15-2024
Stock Market Morning Session: Meme Mania - May 15, 2024
Category: Markets Total Views: 99By : Editor Updated: 05-15-2024
The Rapidly Changing Real Estate Sector - May 14, 2024
Category: Real Estate Total Views: 134By : Editor Updated: 05-14-2024
Today's Stock Market Performance and Overview - May 14, 2024
Category: Stocks Total Views: 140By : Editor Updated: 05-14-2024
Unraveling Mortgage Rates: Insider Views and Housing Challenges
Category: Real Estate Total Views: 178By : Editor Updated: 05-14-2024
Uncovering Buffett's Moves & AI Trends: A Q1 Investing Deep Dive
Category: Investing Total Views: 181By : Editor Updated: 05-14-2024
Earnings Reports: What to Expect on May 14, 2024
Category: Stocks Total Views: 195By : Editor Updated: 05-14-2024
Global Markets: What to watch for - May 14, 2024
Category: Markets Total Views: 161By : Editor Updated: 05-14-2024
10 Easy Steps to Start Trading Stocks Successfully
Category: Stocks Total Views: 248By : Editor Updated: 05-14-2024